Search results for "IMMUNIZATION"

showing 10 items of 313 documents

Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infant…

2007

The immunogenicity and reactogenicity of a meningococcal serogroup C (MenC) conjugate vaccine given concomitantly with DTaP-IPV-HBV/Hib vaccine according to a two- or three-dose schedule in healthy infants was evaluated. At 1 month post-vaccination, 98% (two doses) and 100% (three doses) of subjects had serum bactericidal antibody using human complement assay (hSBA) titres > or =1:8; at 12 months of age > or =89% of subjects in each group remained seroprotected. Induction of immunological memory, as evaluated by administration of a meningococcal serogroup A/C polysaccharide vaccine challenge dose, was similar for both regimens and no interference was observed in the immune response to MenC …

MaleImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineMeningitis Meningococcalmedicine.disease_causeMeningococcal diseaseConjugate vaccinemedicineHumansHepatitis B VaccinesVaccines CombinedHepatitis B AntibodiesBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHepatitis B virusReactogenicityMicrobial ViabilityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityNeisseria meningitidisPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunologyMolecular MedicineFemalebusinessImmunologic MemoryVaccine
researchProduct

Arthus type inflammation with rat immunoglobulins.

1971

Etude comparative des proprietes biologiques des anticorps IgM, IgG1 et IgG2 du rat. Les resultats montrent que le pouvoir agglutinant et lytique des anticorps IgM est respectivement 37 et 100 fois superieur a celui des deux classes d'anticorps IgG. Par contre, en ce qui concerne le phenomene d'Arthus, les anticorps IgM sont moins actifs que les anticorps IgG, si les rapports sont exprimes en poids. Si l'on calcule les rapports par nombre de molecules, les anticorps IgM sont aussi, dans ce cas, plus actifs que les IgG.

MaleImmunodiffusioneducationFreund's AdjuvantImmunoglobulinsInflammationHemolysisChromatography DEAE-CelluloseAntigen-Antibody ReactionsCellular and Molecular NeurosciencemedicineArthus ReactionAnimalsMolecular BiologyPharmacologybiologyChemistryImmune SeraSerum Albumin BovineCell BiologyHemagglutination TestsMolecular biologyRatsMolecular WeightImmunoglobulin Gbiology.proteinMolecular MedicineImmunizationmedicine.symptomAntibodyExperientia
researchProduct

Therapeutic vaccines for cancer: an overview of clinical trials

2014

The therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications …

MaleLung Neoplasmsmedicine.medical_treatmentBreast NeoplasmsActive immunotherapyCancer VaccinesImmune systemAdjuvants ImmunologicCancer immunotherapyAntigens NeoplasmNeoplasmsmedicineHumansCarcinoma Renal CellMelanomaClinical Trials as Topicbusiness.industryImmunotherapy ActiveProstatic NeoplasmsCancerImmunotherapymedicine.diseaseKidney NeoplasmsPancreatic NeoplasmsClinical trialOncologyDrug developmentImmunizationHematologic NeoplasmsUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]ImmunologyFemaleColorectal Neoplasmsbusiness
researchProduct

Hepatitis B virus infection in native versus immigrant or adopted children in Italy following the compulsory vaccination.

2001

Background: Compulsory vaccination of children against hepatitis B virus (HBV) infection was introduced in Italy in 1991. Patients and Methods: To evaluate the current importance of pediatric HBV infection, we studied 359 HBsAg-positive children admitted to 16 centers in Italy from 1991 to 1998. 185 patients were natives of Italy and 174 (39 immigrants and 135 adopted) came from highly endemic countries (eastern Europe: 60.9%, Asia: 16.7%, Africa: 14.9% and Central and South America: 5.7%). Results: Transaminase levels were moderately altered in both Italian (mean 134 UI/l) and foreign children (mean 168 UI/l). In total, 77% of Italian children and 88% of foreign children tested HBeAg posit…

MaleMicrobiology (medical)Hepatitis B virusmedicine.medical_specialtyHBsAgAdolescentmedicine.disease_causeSerologyHepatitis B; vaccination; ItalyAdoptionEpidemiologymedicineHumansHepatitis B VaccinesChildHBV vaccinationHepatitis B virusHepatitis B Surface AntigensImmunization Programsbusiness.industryIncidence (epidemiology)Infantvirus diseasesGeneral MedicineEmigration and ImmigrationHepatitis BvaccinationHepatitis Bmedicine.diseaseAdopted childrendigestive system diseasesVaccinationInfectious DiseasesItalyHBeAgChild PreschoolImmunologyHepatitis B virus hepatitis; Adopted children; Immigrant; HBV vaccinationHepatitis B virus hepatitisFemalebusinessDemographyImmigrant
researchProduct

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

2016

Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naive "Control" participants aged 12, 18 or 24 months…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtypaediatricpersistence of immunityImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineBooster doseMeningitis MeningococcalNeisseria meningitidis Serogroup BPaediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity;Serum bactericidal activityserum bactericidal activity03 medical and health sciences0302 clinical medicine030225 pediatricsOutcome Assessment Health CaremedicineHumansmedia_common.cataloged_instance030212 general & internal medicineToddlerEuropean unionSerogroup B meningococcal vaccineImmunization Schedulemedia_commonMedicine(all)MeningococcalBooster (rocketry)business.industryVaccinationInfantbactericidal antibodiesmedicine.diseaseAntibodies BacterialEuropeVaccinationInfectious DiseasesImmunizationPaediatricChild PreschoolPediatrics Perinatology and Child HealthPersistence of immunityFemaleImmunizationbusinessMeningitisPediatric Infectious Disease Journal
researchProduct

Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine Co-administered with a hib conjugate vaccine either as a si…

2004

A combined DTPa-HBV-IPV/Hib vaccine containing diphtheria (D), tetanus (T), acellular pertussis (Pa), hepatitis B (HBV) and types 1, 2 and 3 inactivated polioviruses (IPV) extemporaneously mixed with a conjugated Haemophilus influenzae type b (Hib) vaccine (Group 1) was compared to the DTPa-HBV-IPV and Hib vaccines (Group 2) administered separately at 3, 5 and 11 months of age (n = 440). A microneutralization assay was used to detect antibodies against the 3 polio virus types (cut-off 1:8 dil), RIA for anti-HBs antibodies (cut-off 10 mIU/ml) and ELISA for antibodies against all other vaccine antigens (cut-off: 0.1 IU/ml for anti-tetanus and anti-diphtheria antibodies; 5 El.U/ml for antibodi…

MaleMicrobiology (medical)Vaccination scheduleEnzyme-Linked Immunosorbent AssayAntibodies ViralInjections IntramuscularRisk Assessmentcomplex mixturesConjugate vaccineGermanyConfidence IntervalsmedicineHumansHepatitis B VaccinesVaccines CombinedBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesProbabilityImmunity CellularReactogenicityGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityDiphtheriaPolysaccharides BacterialVaccinationInfantGeneral MedicineHib Conjugate vaccinemedicine.diseaseAntibodies BacterialVirologyHexavalent combination; DTPa-HBV-IPV combination vaccine; Hib Conjugate vaccineVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesItalyHib vaccineHexavalent combinationImmunologyFemalebusinessDTPa-HBV-IPV combination vaccineFollow-Up StudiesScandinavian Journal of Infectious Diseases
researchProduct

Autoantibodies in experimental autoimmune hepatitis

1992

Experimental autoimmune hepatitis (EAH) can be induced in mice by immunization with syngeneic soluble liver antigens in complete Freund's adjuvant. It has previously been shown that autoreactive T cells play an important role in this animal model of autoimmune hepatitis. We have studied the occurrence of liver autoantibodies in EAH. Characteristic autoantibodies appeared several weeks after disease induction and antibody titres continued to rise when histological and biochemical signs of disease activity had already regressed. Autoantibodies in EAH seemed to recognize autoantigens other than those present in autoimmune chronic active hepatitis patients. We conclude that autoantibodies arise…

MalePathologymedicine.medical_specialtyBlotting WesternFluorescent Antibody TechniqueAutoimmune hepatitisHepatitis Animalmedicine.disease_causeAutoimmune DiseasesAutoimmunityPathogenesisMiceAntigenAnimalsMedicineAutoantibodiesHepatitisHepatologybiologybusiness.industryAutoantibodymedicine.diseaseMice Inbred C57BLImmunizationImmunologybiology.proteinAntibodybusinessJournal of Hepatology
researchProduct

Antimetastatic Effect of Immunization with Liposome-Encapsulated Tumor Cell-Membrane Proteins Obtained from Experimental Tumors

1995

Immunization of C57BL/6 mice with tumor-derived membrane-proteins encapsulated in sized liposomes (0.2 microgram/mouse) and composed by phosphatidylcholine or sphingomyelin, significantly reduced the mean values of spontaneous lung metastasis from both B16 (0.7 +/- 0.5 and 1.2 +/- 0.6, respectively) and 3LL (4.8 +/- 2.5 and 7.2 +/- 4.1, respectively) tumors, with respect to control (HEPES) groups (4.8 +/- 1.1 and 19.0 +/- 4.4, respectively). However, no significant antimetastatic effect was observed using free tumor-derived proteins (2 micrograms/mouse) or liposome vehicle alone. Specific humoral immune response after the vaccination was studied by flow cytometry of tumor cells incubated wi…

MalePathologymedicine.medical_specialtyLung NeoplasmsImmunologyMelanoma ExperimentalIn Vitro TechniquesBiologyToxicologyFlow cytometryMicechemistry.chemical_compoundImmune systemAntigens NeoplasmAntimetastatic AgentmedicineAnimalsImmunology and AllergyPharmacologyHEPESLiposomemedicine.diagnostic_testCell MembraneAntibody-Dependent Cell CytotoxicityLewis lung carcinomaGeneral MedicineMolecular biologyMice Inbred C57BLchemistryAntigens SurfaceLiposomesHumoral immunitybiology.proteinImmunizationAntibodySpleenImmunopharmacology and Immunotoxicology
researchProduct

Surveillance Data for Eight Consecutive Influenza Seasons in Sicily, Italy

2019

Influenza A and B outbreaks occur each year with different activity and molecular patterns. To date, knowledge of seasonal epidemiology remains a prerequisite not only to put in place the most effective immunization strategy against influenza but also to identify population groups at higher risk of developing serious complications. A retrospective analysis of influenza surveillance data from 2010 to 2018 aimed to explore the epidemiology of influenza in Sicily, at the primary care and hospital level. Overall, 6,740 patients with acute respiratory infection were tested, of which 3,032 (45.0%) were positive for influenza. The relative proportion of type A and B viruses markedly varied across …

MalePediatricsCommunityDiseaseSettore MED/42 - Igiene Generale E ApplicataSeverity of Illness IndexDisease Outbreakslaw.inventionRisk FactorslawEpidemiologyChildRespiratory Tract InfectionsSicilyeducation.field_of_studyVaccinationRespiratory infectionArticlesMiddle AgedIntensive care unitHospitalizationIntensive Care UnitsInfectious DiseasesMolecular surveillanceInfluenza A virusChild PreschoolEpidemiological MonitoringFemaleSeasonsAdultmedicine.medical_specialtyAdolescentPopulationYoung AdultVirologyInfluenza HumanmedicineHumanseducationAgedRetrospective Studiesbusiness.industryInfantOutbreakmedicine.diseaseObesityInfluenzaInfluenza B virusImmunizationParasitologyRisk factorbusinessThe American Journal of Tropical Medicine and Hygiene
researchProduct

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a mu…

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Uni…

MalePediatricsefficacyHIV InfectionsBooster doselaw.invention0302 clinical medicineRandomized controlled triallaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesvaccineSingle-Blind Method030212 general & internal medicineVaccines Synthetic0303 health sciencesnumberinfected patientMiddle AgedHepatitis BHepatitis B3. Good healthVaccinationTreatment OutcomeInfectious Diseaseshomosexual man[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemaleFranceViral hepatitisAdultmedicine.medical_specialtyHepatitis B vaccineImmunization SecondaryvirusYoung Adult03 medical and health sciencesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedIntention-to-treat analysis030306 microbiologybusiness.industrymedicine.diseaserateRegimeninjection[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessimpaired response
researchProduct